Boehringer's cancer drug Giotrif gains European marketing authorization

German family-owned drugs majorBoehringer Ingelheim has been granted marketing authorization from the European Commission for Giotrif (afatinib) as first line treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).

Giotrif is the first irreversible ErbB family blocker is a new, once-daily, oral treatment which targets EGFR. The marketing authorization follows recent guidance from the UK’s National Institute for Health and Care Excellence (NICE) highlighting the clinical need for EGFR testing to detect the mutation in untreated patients with advanced or metastatic NSCLC.

Will join a market sector forecast to reach $7.9 billion in 2022